BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 20, 2025
Home » Authors » John Brosky

Articles by John Brosky

Elekta inks $100M deal with Genesiscare, grabbing larger market share in Australi

April 4, 2016
By John Brosky
PARIS – Elekta Instrument AB closed a strategic partnership agreement it values at $100 million with radiation oncology specialist Genesiscare Ltd. Elekta's Chief Commercial Officer Ian Alexander told Medical Device Daily, "This is the largest deal we have ever closed, and it is significant on a number of levels."
Read More

Nexstim to bring failed sham trial for stroke device to FDA, hoping for success

April 1, 2016
By John Brosky
PARIS – Here's a puzzler that will leave you scratching your head. Say a therapeutic treatment fails to meet the end point in a clinical trial because the sham group did almost as well as the target patient group. Do you take the device to the FDA with a 510k denovo application?
Read More

Tappy says to reach value in med-tech, one must go all the way with a firm

March 29, 2016
By John Brosky

Investors pump fresh cash into dedicated med-tech venture fund

March 28, 2016
By John Brosky
Last week, Endeavour Vision SA from Geneva, Switzerland announced it had closed the largest venture capital fund ever to be dedicated exclusively to medical technologies. Medtech Growth Limited Partners holds €250 million ($279 million) to be focused on late-stage medical device start-ups, and more specifically, those with a digital health component in their products.
Read More

MIT polymer raises $25 million in early stage deal for Gecko Biomedical

March 23, 2016
By John Brosky
PARIS – Would you pay $25 million to come in on the ground floor of Super Glue?
Read More

MDxhealth aims to disrupt U.S. prostate market for biopsy, MRI exams

March 21, 2016
By John Brosky

Roche deal pumps up Cellnovo prospects for insulin delivery

March 16, 2016
By John Brosky

The need for speed drives MRI sales with accelerated workflow

March 7, 2016
By John Brosky

Cloud computing to break grip of PACS on medical imaging

March 4, 2016
By John Brosky
VIENNA – Ready or not, radiology is going to the cloud. And radiologists are definitely not ready, stubbornly continuing with unstructured reports that defy data analytics and hospital-based dedicated workstations for picture archiving and communication systems (PACS).
Read More

Tomosynthesis still stuck at starting gate as screening tool

March 3, 2016
By John Brosky
Previous 1 2 … 9 10 11 12 13 14 15 16 17 … 101 102 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing